Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $1.7 million.

  • Heron Therapeutics' Capital Expenditures was N/A to $208,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is 10.42% up from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Capital Expenditures is $1.7 million, which was up 10.42% from $1.5 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Capital Expenditures registered a high of $6.8 million during FY2020, and its lowest value of $1.5 million during FY2023.
  • For the 3-year period, Heron Therapeutics' Capital Expenditures averaged around $1.7 million, with its median value being $1.7 million (2024).
  • Per our database at Business Quant, Heron Therapeutics' Capital Expenditures slumped by 55.64% in 2021 and then rose by 10.42% in 2024.
  • Over the past 5 years, Heron Therapeutics' Capital Expenditures (Yearly) stood at $6.8 million in 2020, then tumbled by 55.64% to $3.0 million in 2021, then crashed by 39.61% to $1.8 million in 2022, then decreased by 15.34% to $1.5 million in 2023, then grew by 10.42% to $1.7 million in 2024.